AI Verdict
LLY has stronger fundamentals based on our AI analysis.
LLY vs REGN Fundamental Comparison
| Metric | LLY | REGN |
|---|---|---|
| Revenue | $19.8B | $3.6B |
| Net Income | $7.4B | $727.2M |
| Net Margin | 37.4% | 20.2% |
| ROE | 23.7% | 2.3% |
| ROA | 6.3% | 1.8% |
| Current Ratio | 1.50x | 3.57x |
| Debt/Equity | 1.26x | 0.06x |
| EPS | $8.26 | $6.75 |
Green = Better metric | Red = Weaker metric
You Might Also Compare
LLY vs REGN: Frequently Asked Questions
Is LLY or REGN a better buy in 2026?
Based on dual AI fundamental analysis (Claude and ChatGPT), LLY has stronger fundamentals. LLY is rated BUY (86% confidence) while REGN is rated BUY (80% confidence). This is not investment advice.
How does LLY compare to REGN fundamentally?
ELI LILLY & Co has ROE of 23.7% vs REGENERON PHARMACEUTICALS, INC.'s 2.3%. Net margins are 37.4% vs 20.2% respectively.
Which stock pays higher dividends, LLY or REGN?
LLY has a dividend yield of N/A or no dividend while REGN has N/A or no dividend. Check individual stock pages for detailed dividend history and payout ratios.
Should I invest in LLY or REGN for long term?
For long-term investing, consider that LLY has BUY rating with 86% confidence, while REGN has BUY rating with 80% confidence. Higher confidence indicates more consistent fundamentals from SEC filings. This is not investment advice - always do your own research.
What do the AI models say about LLY vs REGN?
Our dual AI system (Claude by Anthropic and ChatGPT by OpenAI) analyzes SEC 10-K and 10-Q filings independently. For LLY vs REGN, the AI consensus favors LLY based on fundamental metrics including revenue growth, profitability, ROE, and balance sheet strength.